Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management

[1] DeFronzo RA(2021)Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors Nat Rev Nephrol 17 319-334

[2] Reeves WB(2017)Diabetic kidney disease: challenges, progress, and possibilities Clin J Am Soc Nephrol 12 2032-2045

[3] Awad AS(2020)Neutrophil gelatinase-associated lipocalin and retinol-binding protein-4 as biomarkers for diabetic kidney disease Kidney Blood Press Res 45 222-232

[4] Alicic RZ(2017)Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy Can J Kidney Health Dis 4 2054358117705371-888

[5] Rooney MT(1995)Advanced glycosylation end products in diabetic renal and vascular disease Am J Kidney Dis 26 875-2043

[6] Tuttle KR(2004)Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway Am J Pathol 165 2033-360

[7] Abbasi F(2010)RAGE and the pathogenesis of chronic kidney disease Nat Rev Nephrol 6 352-84

[8] Moosaie F(2012)Early renal function decline in type 2 diabetes Clin J Am Soc Nephrol 7 78-412

[9] Khaloo P(2010)Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 31 462-1876

[10] Firouzabadi FD(2019)New pharmacological strategies for protecting kidney function in type 2 diabetes Lancet Diabetes Endocrinol 7 397-560

[1] DeFronzo RA(2021)Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors Nat Rev Nephrol 17 319-334

[2] Reeves WB(2017)Diabetic kidney disease: challenges, progress, and possibilities Clin J Am Soc Nephrol 12 2032-2045

[3] Awad AS(2020)Neutrophil gelatinase-associated lipocalin and retinol-binding protein-4 as biomarkers for diabetic kidney disease Kidney Blood Press Res 45 222-232

[4] Alicic RZ(2017)Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy Can J Kidney Health Dis 4 2054358117705371-888

[5] Rooney MT(1995)Advanced glycosylation end products in diabetic renal and vascular disease Am J Kidney Dis 26 875-2043

[6] Tuttle KR(2004)Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway Am J Pathol 165 2033-360

[7] Abbasi F(2010)RAGE and the pathogenesis of chronic kidney disease Nat Rev Nephrol 6 352-84

[8] Moosaie F(2012)Early renal function decline in type 2 diabetes Clin J Am Soc Nephrol 7 78-412

[9] Khaloo P(2010)Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 31 462-1876

[10] Firouzabadi FD(2019)New pharmacological strategies for protecting kidney function in type 2 diabetes Lancet Diabetes Endocrinol 7 397-560